the official answer is nothing or not much, as peak sales are estimated around 500mil.
I agree with you 3-5 bucks and the milestone will help determine what the peak sales outside the US will be. Doubt anyone would pay 40-150 mil milestone for something with worldwide sales of 500mil when omeros is going to sell the product themselves in the US. My guess on the milestone 40-150 mil (orex got 50 mil before approval and I think 100mil on FDA approval with two other drugs in the market. omidria has no competition)
looking at clinical trial dot gov and if updated the final collection date is during March 2015.
Estimated Enrollment: 36
Study Start Date: January 2014
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
SEATTLE, March 9, 2015 /PRNewswire/ -- Omeros Corporation OMER, -4.36% a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its fourth quarter and full-year 2014 financial results for the period ended December 31, 2014, on Monday, March 16, 2015, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results.
Conference Call Details
To access the live conference call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The participant passcode is 1480892. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 1480892
I do not think they will sell either. Premium would not be as high with EU pending. chtp when they sold part of the sales price was 50 cents a share for each year for 3 years if the sales target was hit. with EU pending they can make it so there is a payment to shareholders of record end of trading.
i don't think any type of buyout is going on right now, but if so, i have no problem with it - as long as they fetch us a big fat premium.
qcor and chtp did not have a CC as they were being purchased (owned both). If there is no CC there is a good chance they are in talks to be purchased. odds are there will be a CC, but I do not want one
I get a due date of 3/16. Should hear from the company today or tomorrow about a CC for Monday. Hope they just file and no CC.
Going forward they may need to file the 10k within 60 days of year end vs 75. Large accelerated filers with 700mm or more have 60 days vs 75 days for filers 75-700mm.
I am also interested to see what calculation he has. My guess he must of purchased the stock around 27. Not late to the party but not early like us
I have not read the articles, but pretty sure they mention the stock is cheap. NSPS was purchased for around 5 billion (rare diseases sales this year est of 500mil with pipeline). omidria should have sales exceeding 1 bil (in two years 25mil procedures worldwide great chance to exceed 1 bil). Plus if there is a patent on omidria may give it a useful life greater than 7 years before generics can enter. EU approval and better chance of us getting purchased and me moving onto other bios
There were 3 articles in the WSJ on biotechs and Pharmacyclics. Whether Omeros wants to sell or not, this type of action usually increases the value of all biotech stocks.
"Biotech Bidding War Yields Rich Price"
"How Much Is One Cancer Drug Worth?"
"AbbVie’s Expensive Growth Tonic"